Polymorphism in CYP2C9 as a non-critical factor of warfarin dosage adjustment in Korean patients.

@article{Lee2003PolymorphismIC,
  title={Polymorphism in CYP2C9 as a non-critical factor of warfarin dosage adjustment in Korean patients.},
  author={Sukhyang Lee and J Kim and C V Chung and Kyoung Joo Cho and Jeong Hee Kim},
  journal={Archives of pharmacal research},
  year={2003},
  volume={26 11},
  pages={967-72}
}
Cytochrome P4502C9(CYP2C9) is largely responsible for terminating anticoagulant effect by hydroxylation of S-warfarin to inactive metabolites. Mutations in the CYP2C9 gene result in the expression of allelic variants, CYP2C9*2 and CYP2C9*3 with reduced enzyme activity compared to wild type CYP2C9*1. The aim of this study was to assess relationship between… CONTINUE READING